Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Gynecologic 1Dermatologic 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Bronchiolitis Obliterans Syndrome 1

Interventions

fludarabine phosphate 140Cyclophosphamide 132Busulfan 102Peripheral Blood Stem Cell Transplantation 95Imatinib Mesylate 94Mycophenolic Acid 91Cytarabine 82Azacitidine 80Tacrolimus 79Cyclosporine 78Whole-Body Irradiation 77fludarabine 74Antilymphocyte Serum 71Methotrexate 65Filgrastim 63nilotinib 59Melphalan 51Decitabine 50Radiotherapy 43Dasatinib 34Granulocyte Colony-Stimulating Factor 33ruxolitinib 31Clofarabine 31Etoposide 30thymoglobulin 29Thiotepa 29Cord Blood Stem Cell Transplantation 28sargramostim 27Methylprednisolone 26Stem Cell Transplantation 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Vision, Ocular × Myeloid × Clear all
NCT02085798 2020-01-27

Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)

Celgene

Completed
503 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡